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Abstract
Objectives: This study was conducted to compare 10-year survivors with patients who survived
<10 years in a large Western series of patients submitted to hepatectomy for hepatocellular carcinoma
(HCC).
Methods: A retrospective review of a series of hepatic resections conducted in a referral centre for HCC
between January 1987 and October 2002 was conducted.
Results: A total of 176 patients were analysed. Twenty-eight patients survived ≥ 10 years (Group A) and
were compared with the 148 patients who did not (Group B). Group A had smaller tumours (5.7 cm versus
8.2 cm; P = 0.001) and a lower incidence of microvascular invasion (18.5% versus 37.1%; P = 0.004).
Recurrence did not differ significantly (Group A 18/28, 64.3% versus Group B 94/148, 63.5%). Median
time to recurrence was longer in Group A (70 months versus 15 months; P < 0.0001), and more patients
in Group A were able to undergo curative treatment for recurrence (88.8% versus 40.4%; P < 0.0001).
Multivariate analysis showed that lack of vascular invasion (P = 0.020), absence of perioperative trans-
fusion (P = 0.014), and recurrence at >2 years after primary resection (P = 0.045) were significantly
associated with 10-year survival.
Conclusions: Ten-year survival after liver resection for HCC can be expected in approximately 15% of
patients. Recurrence does not preclude longterm survival. Recurrence at >2 years after resection,
absence of vascular invasion, and absence of perioperative transfusion are independently associated
with 10-year survival.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the third most frequent cause of cancer-related
deaths worldwide.1 Hepatic resection remains the treatment of
choice for single HCC in patients with preserved liver function.2
Clinically significant portal hypertension and high total bilirubin
(≥1.0 mg/dl) are generally regarded as contraindications for
resection.3 According to these criteria, only about 20% of
patients with HCC would be considered ideal candidates for
resection.
Despite a large number of series reporting outcomes of hepatic
resection for HCC, actual 10-year follow-up and survival data are
seldom reported.4–7 A recent meta-analysis of 14 retrospective
series found that only 303 actual 10-year survivors had been
reported in the world literature over a 20-year span. This trans-
lated into an actual 10-year survival rate of only 7%.8
A high rate of recurrence after resection is thought to be the
major impediment to longterm survival. In large series of resec-
tions performed for HCC, recurrence is generally reported to
exceed 60% at 5 years and survival at 5 years is reported to be
between 40–50%.4–7 Recurrence most commonly occurs during
the first 2 years and has been shown to be mostly attributable to
true metastases from the resected tumour during this early
period.9,10 De novo tumours, accounting for the majority of late
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recurrences, arise in patients with underlying liver disease and
their incidence increases with time.10,11
The aim of this study was to identify and characterize patients
who have survived for ≥10 years after primary hepatic resection
for HCC and to identify the variables associated with 10-year
survival.
Materials and methods
This study was approved by the study centre’s institutional review
board. Subsequently, data for all primary liver resections per-
formed for HCC from January 1987 to October 2002 were col-
lected from a prospectively maintained database and reviewed
retrospectively. Follow-up was complete until October 2012,
allowing for a 10-year follow-up of all survivors. Patients lost to
follow-up were excluded from the study. Patients were divided
into two groups; Group A included only patients who survived
≥10 years after resection and Group B comprised those who died
at < 10 years. The terms ‘10-year survivors’ and ‘longterm survi-
vors’ will be used interchangeably.
Criteria for primary resection
Patients were required to have a single tumour on imaging and the
absence of extrahepatic spread. Inclusion criteria for resection also
required patients to demonstrate Child–Pugh class A liver func-
tion. Prior to 1995, a few patients with Child–Pugh class B liver
function were offered resection. Evidence of portal hypertension
on imaging or a platelet count of < 100 000/μl was not a contrain-
dication for resection prior to 2002. A transjugular portocaval
gradient of >10 mmHg was considered to contraindicate surgery
after 2002 and was measured in patients with low platelet counts
and no radiographic signs of portal hypertension (splenomegaly
or variceal veins) and in those with previous splenectomy in
whom platelet count cannot be used as a surrogate for portal
hypertension. Gross vascular invasion was not considered a con-
traindication to resection as long as the main portal vein and the
branch to the remaining portion of the liver were patent. Barce-
lona Clinic Liver Cancer (BCLC) staging was used to guide deci-
sion making, but resection was not limited to class A patients
because segmental vascular involvement and tumours measuring
>5 cm were not considered to contraindicate surgery.12 Patients
were discussed weekly in a multidisciplinary conference as sug-
gested by American Association for the Study of Liver Disease
(AASLD) guidelines.3
Follow-up protocol
Patients were followed with contrast-enhanced computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) of the
abdomen and non-contrast CT of the chest every 3 months
during the first year after resection, every 4 months during the
second year, and every 6 months subsequently. Serum alpha-
fetoprotein (AFP) was measured at the same intervals.
The diagnosis of intrahepatic recurrence was based on imaging
alone if the tumour displayed enhancement characteristics typical
of HCC. Extrahepatic tumours and those with atypical imaging
characteristics were biopsied to confirm HCC.
Variables studied
Twenty-two variables divided into four subgroups were identified.
Preoperative variables included age, gender, BCLC classification,
portal hypertension (on axial imaging and/or based on a platelet
count of < 100 000/μl), AFP levels, and underlying liver disease
[including hepatitis B and C viruses (HBV, HCV), alcoholic liver
disease and other conditions (haemochromatosis, primary biliary
cirrhosis, primary sclerosing cholangitis and cryptogenic cirrho-
sis)]. Perioperative variables included major resection (three or
more segments), need for transfusion and portal thrombectomy.
Pathological variables were identified through the systematic
review of specimens for the presence and degree of fibrosis
(Scheuer fibrosis stage), largest tumour diameter, tumour differ-
entiation, degree of vascular invasion, presence of satellites, and
positive margin status (defined as tumour cells on the cut surface
of the resection). Postoperative variables were concentrated
mainly in recurrence data and included the number of liver
tumours at recurrence, AFP level and BCLC class at recurrence,
site of recurrence, time to recurrence and treatment of recurrence.
Treatment options after recurrence included potentially curative
treatments, such as a second resection, liver transplant, ablation
(radiofrequency or ethanol ablation), and non-curative treat-
ments, including transarterial embolization (bland or chemoem-
bolization) and other treatments (systemic chemotherapy and/or
external beam radiation).
Statistical analysis
Descriptive statistics are reported as the percentage or as the mean
± standard deviation (SD). Categorical data were compared using
the chi-squared test. Continuous data were analysed with t-tests.
Survival was calculated in months from the time of initial hepa-
tectomy until the last clinical or telephone encounter, or death.
Clinically relevant variables that were significant on univariate
analysis were entered into a multivariate binary logistic Cox
regression model to identify independent predictors of outcome.
Recurrence and time to recurrence were included to evaluate their
impact on survival. Overall survival and recurrence curves were
generated using the Kaplan–Meier method and compared using
the log-rank test. Statistical analysis was performed using IBM
spss Statistics for Windows Version 20.0 (IBM Corp., Armonk,
NY, USA). P-values of ≤0.05 were considered to indicate statistical
significance.
Results
During the time period under study, 210 patients with HCC
underwent hepatic resection as primary treatment, of whom 34
(16.2%) were lost to follow-up. The study population comprises
the remaining 176 patients.
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Of these 176 patients, 28 (15.9%) survived ≥10 years and were
labelled as Group A. The remaining 148 (84.1%) patients survived
for < 10 years and represent Group B. The mean length of
follow-up in the entire series was 28 months. All survivors were
followed for ≥10 years. Overall survival and recurrence curves are
shown in Fig. 1.
Baseline characteristics are displayed in Table 1. Perioperative
variables and pathological data are shown in Table 2. Variables
related to recurrence are recorded in Table 3. The absolute rates of
recurrence were almost identical in the two groups [18 of 28
patients (64.3%) versus 94 of 148 patients (63.5%); P = 0.938].
However, Kaplan–Meier analysis and the log-rank test indicated
that recurrence was significantly higher in Group B (P = 0.001) as
shown in Fig. 2. Early recurrence was far more common in Group
B. Median time to recurrence was 70.8 months in Group A and
12.1 months in Group B (P < 0.0001). Recurrence within 2 years
was observed in six of 18 Group A patients and 80 of 94 Group B
patients (P < 0.0001). Patients in Group A showed significantly
better BCLC scores at the time of recurrence, which increased
their eligibility for curative treatment. All 18 patients in Group A
were treated for their recurrence as noted in Table 3, whereas 10 of
the 94 patients in Group B received only supportive care.
Multivariate analysis showed the absence of perioperative trans-
fusion, the absence of vascular invasion and recurrence at >2 years
to be independently associated with 10-year survival (Table 4).
Discussion
This study presents a large series of patients submitted to resection
for HCC with actual 10-year survival data; these longterm survi-
vors are the focus of the paper. Few series, particularly in theWest,
are large enough and have long enough follow-up to provide
robust actuarial outcomes for HCC patients 10 years after resec-
tion, much less actual survival data. A recent meta-analysis found
an actual 10-year survival rate of 7.2%.8
Although hepatic resection is considered a potentially curative
treatment for HCC, approximately 70% of patients will develop
recurrence within 5 years. The present study confirms this:
Kaplan–Meier curves for the entire cohort show that 75.3% of
patients experienced recurrence within 5 years and 82.1% did so
within 10 years. Of note, recurrence was as common among
10-year survivors as it was in those who died within 10 years of
resection in absolute numbers, but, when calculated using the
Kaplan–Meier method, the rate of recurrence was statistically
higher in Group B. This, however, represents an anomaly of the
Kaplan–Meier method. The rate of recurrence is calculated based
on the number of patients at risk at a certain time-point. Thus, as
none of the patients in Group A died, the denominator in this
group remained constant. As patients in Group B died, the
denominator in this group became progressively smaller and the
proportion of the remaining population at risk increased. Thus,
although absolute rates of recurrence were the same in both
groups, Kaplan–Meier analysis showed the percentage of patients
experiencing recurrence to be higher in Group B.
The most substantial differences between longterm survivors
and the rest of the HCC resection population pertained to the
‘when, where and how’ aspects of recurrence rather than the ‘if ’.
On univariate analysis, 10-year survivors were found to experi-
ence recurrence later, were more likely to have a single recurrence
in the liver, had a better BCLC score at recurrence and received
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Figure 1 Kaplan–Meier curves showing (a) overall survival and (b) recurrence in the entire cohort of 176 patients submitted to hepatectomy
for hepatocellular carcinoma
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Table 1 Baseline characteristics of patients submitted to resection for hepatocellular carcinoma who did (Group A) and did not (Group B)
survive for ≥10 years after resection (n = 176)
Preoperative characteristics Group A
(n = 28, 15.9%)
Group B
(n = 148, 84.1%)
P-value
Age, years, mean ± SD 60.8 ± 12.1 57.5 ± 11.4 0.191
Male gender, n (%) 19 (67.9%) 107 (72.3%) 0.633
Underlying liver disease, n (%) 0.012
Hepatitis B virus 15 (53.6%) 30 (20.3%)
Hepatitis C virus 9 (32.1%) 59 (39.9%)
Other 1 (3.6%) 23 (15.5%)
None 3 (10.7%) 36 (24.3%)
Stage 3–4 fibrosis, n (%) 15 (53.6%) 89 (60.1%) 0.517
Platelets <100 000/μl
(Missing data: 12, 6.8%)
5 (21.0%) 21 (15.2%) 0.489
AFP, mean ± SD
(Missing data: 28, 15.9%)
7567 ± 33 070 6903 ± 60 350 0.926
AFP of >400 ng/ml, n (%) 7 (29.2%) 40 (32.3%) 0.766
BCLC class at presentation, n (%)
(Missing data: 12, 6.8%)
0.378
A 18 (66.7%) 68 (48.9%)
B 3 (11.1%) 26 (18.7%)
C 6 (22.2%) 43 (30.9%)
SD, standard deviation; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.
Table 2 Perioperative and pathological factors affecting longterm survival in patients submitted to resection for hepatocellular carcinoma
who did (Group A) and did not (Group B) survive for ≥10 years after resection (n = 176)
Factors Group A
(n = 28, 15.9%)
Group B
(n = 148, 84.1%)
P-value
Perioperative factors
Major resection (>3 segments), n (%) 11 (39.3%) 77 (52.0%) 0.204
Portal thrombectomy, n (%) 1 (3.6%) 19 (12.8%) 0.154
Required transfusion, n (%)
(Missing data: 5, 2.8%)
8 (28.6%) 82 (57.3%) 0.005
Pathological factors
Largest diameter, cm, mean ± SD
(Missing data: 6, 3.4%)
5.7 ± 3.1 8.2 ± 5.2 0.001
Largest diameter >5 cm, n (%) 11 (40.7%) 92 (64.3%) 0.021
Tumour differentiation, n (%)
(Good/moderate/poor)
(Missing data: 25, 14.2%)
10 (38.5%)/12 (46.2%)/4 (15.4%) 42 (33.6%)/59 (47.2%)/24 (19.2%) 0.851
Margin positive resection, n (%)
(Missing data: 9, 5.1%)
1 (3.6%) 9 (6.5%) 0.581
Satellites, n (%)
(Missing data: 8, 4.5%)
8 (28.6%) 68 (48.6%) 0.075
Vascular invasion, n (%)
(Missing data: 6, 3.4%)
0.001
None 15 (55.6%) 34 (23.8%)
Micro 5 (18.5%) 53 (37.1%)
Gross 7 (25.9%) 56 (39.2%)
SD, standard deviation.
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curative treatment for recurrence (second resection, transplant or
radiofrequency ablation) more frequently.
Tumour size has been linked repeatedly to recurrence and sur-
vival across multiple studies.A direct relationship between the size
and degree of vascular invasion is also well known, and vascular
invasion is, by itself, a well-defined predictor of poor outcome.13–15
In this study, the mean tumour size in both groups was relatively
large (>5 cm.). Longterm survivors in this study had significantly
smaller tumours and were less likely to have vascular invasion
on univariate analysis. Microvascular invasion was found to be
significantly different in univariate analysis (P = 0.004), but
remained independently associated with 10-year survival on mul-
tivariate analysis only when clustered together with gross vascular
invasion. Another known predictor of poor outcome is need for
transfusion; GroupA had significantly less need for transfusion on
univariate and multivariate analyses.4,16 Although it was not sta-
tistically significant, a trend toward higher percentages in Group B
emerged in relation to thrombectomy and the presence of satellite
nodules, both of which are regarded as ominous.17,18
The distribution of underlying liver disease in this series reflects
the heterogeneity of the population. Univariate analysis showed
Table 3 Postoperative factors affecting longterm survival in patients submitted to resection for hepatocellular carcinoma who did (Group A)
and did not (Group B) survive for ≥10 years after resection (n = 176)
Factors Group A
(n = 28, 15.9%)
Group B
(n = 148, 84.1%)
P-value
Recurrence, n (%) 18 (64.3%) 94 (63.5%) 0.938
Intrahepatic/intra-extra/extrahepatic, n (Missing data: 1, 0.5%) 16/2/0 54/26/13 0.049
Single recurrence, n
(Missing data: 16, 14.3%)
13/18 30/94 0.009
Recurrence at < 2 years, n 6/18 80/94 <0.001
BCLC class A/B/C/D, n
(Missing data: 19, 17.0%)
12/0/2/0 27/9/39/4 0.006
AFP at recurrence, ng/ml, mean ± SD
(Missing data: 28, 25.0%)
7340 ± 26 219 4723 ± 21 964 0.702
AFP >400 ng/ml, n (%) 2 (15.4%) 15 (21.1%) 1.000
Type of treatment after recurrence, n (%)
(Missing data: 11, 9.8%)
18 (64.3%) 94 (63.5%) 0.010
Re-resection 5/18 8/94
Transplant 8/18 14/94
Radiofrequency ablation 3/18 16/94
Transarterial chemoembolization 1/18 19/94
Other (chemotherapy and/or radiation) 1/18 16/94
Supportive care – 10/94
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; SD, standard deviation.
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Figure 2 Kaplan–Meier curves for recurrence in patients who did and
did not achieve 10-year survival after hepatectomy for hepatocellular
carcinoma. LTS, longterm survivors
Table 4 Multivariate analysis of factors affecting longterm survival in
all patients submitted to resection (n = 176)
P-value
Pathological factors, n (%)
Vascular invasion, yes 0.020
Tumour diameter of >5 cm 0.192
Intraoperative factors, n (%)
Blood transfusion (yes/no) 0.014
Recurrence-related factors, n (%)
Recurrence in < 2 years 0.045
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that significantly more patients with HBV were longterm survi-
vors in this series, suggesting that HCC in association with HBV
may have a more favourable prognosis. Conflicting results have
emerged in previous research pertaining to this association,
including a large multicentre study by Pawlik et al.19–22 Other
preoperative factors that have been reported to impact prognosis,
such as the presence of stage III–IV fibrosis and low platelet count
(a surrogate for severe fibrosis),23 did not differ between the
groups in this study.
In this series only 35.7% (10 of 28) of longterm survivors
remained recurrence-free at 10 years. A recent Japanese study
showed that 14 of 74 (18.9%) patients who were disease-free at
10 years after resection for HCC eventually developed recurrence,
prompting the authors to suggest lifelong follow-up.24 Delayed
recurrence in longterm survivors is likely to represent de novo
HCC rather than the progression of occult metastatic disease.10,11
Conclusions
Ten-year survival after liver resection for HCC is possible and can
be expected in approximately 16% of patients. Recurrence alone
does not preclude longterm survival. Lack of vascular invasion,
absence of perioperative transfusions and time to recurrence of >2
years were independent factors associated with 10-year survival.
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